Welcome to our dedicated page for Canaquest Medica news (Ticker: CANQF), a resource for investors and traders seeking the latest updates and insights on Canaquest Medica stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Canaquest Medica's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Canaquest Medica's position in the market.
CanaQuest Medical Corp (OTC: CANQF) has announced strategic additions to its executive team to advance its drug candidate CQ-001 through clinical trials. Dr. Jordyn Stuart, with extensive experience in cannabinoid therapeutics, and Dr. Paul Dick, a veteran in pharmaceutical product development, have joined as Lead Scientific Advisor and Chairman of the Advisory Board, respectively.
Dr. Stuart's background includes the FDA-approved launch of Epidiolex at Greenwich Biosciences, while Dr. Dick brings over 30 years of experience in pharmaceutical and animal health industries.
Preclinical trials on rodents showed positive effects on anxiety and memory, and a preclinical epilepsy model demonstrated a 35% increase in potency for CQ-001 compared to isolated CBD. CanaQuest has also been named the Endocannabinoid Therapeutics Development Company of the Year 2024 by Global Health & Pharma, UK.
Summary not available.
Summary not available.
Summary not available.
CanaQuest Medical Corp. (OTC PINK: CANQF) announced a Master Service Agreement with Neeka Health to conduct multiple clinical studies evaluating the efficacy of Mentanine on populations facing transitional issues. The partnership aims to enhance the quality of life for these groups by integrating Neeka's peer support platform with CanaQuest's cannabinoid therapeutics. Neeka is known for its innovative approach in digital health and decentralized clinical trials, while its leadership includes Dr. Hunter Land, a notable figure in cannabinoid research. CanaQuest's drug candidate CQ-001 is set for clinical trials targeting epilepsy, supported by positive pre-clinical results. This collaboration positions both companies toward advancing their research in cannabinoid-based treatments.
CanaQuest Medical Corp (OTC PINK:CANQF) has announced significant results from its clinical efficacy study involving drug candidate CQ-001, which combines cannabidiol (CBD) with an innovative formulation. The study showed a 40% greater reduction in seizures at medium doses compared to standard CBD, signifying CQ-001's enhanced efficacy. This research, led by Dr. W McIntyre Burnham, supports pre-clinical findings and positions CQ-001 for a future Phase II/III trial. The company aims to secure regulatory approval for CQ-001 in treating epilepsy within three years.
CanaQuest Medical Corp (OTC PINK: CANQF) has launched its all-natural product, Mentanine®, in California, aimed at enhancing mental health. The formulation combines cannabidiol (CBD) with Omega-3s and is designed to cross the blood-brain barrier, showing effectiveness in tackling anxiety, depression, PTSD, and related conditions. Backed by pre-clinical trials published in the European Journal of Neuroscience, this product claims to improve mental clarity, sleep quality, and reduce joint stiffness. The announcement reflects CanaQuest's ongoing commitment to drug discovery within the endocannabinoid system.
CanaQuest Medical Corp (OTC PINK:CANQF) has appointed Rob Rinderman as its new Director of Communications. Rinderman, with over 35 years of experience in Wall Street investment, will advance investor relations and corporate communications. President Paul Ramsay emphasized that Rinderman's seasoned background will enhance the company's outreach at this pivotal time, coinciding with regulatory advancements and successful pre-clinical trials. CanaQuest, focused on cannabinoid-based health products, is preparing for an e-commerce launch and has received international award recognition.
Summary not available.
CanaQuest Medical Corp (OTC PINK:CANQF) announced that Fundamental Research Corp (FRC) has initiated coverage with a BUY rating. FRC, a top independent research house, highlighted the potential of CanaQuest's cannabinoid formulations for mental health therapies. The report suggested a fair value estimate of US$0.78 per share. FRC noted that the company's success hinges on management's ability to secure financing and regulatory approvals. CanaQuest is focused on developing products targeting mental health conditions, with two Master Formulations identified for Drug Identification Numbers.
FAQ
What is the current stock price of Canaquest Medica (CANQF)?
What is the market cap of Canaquest Medica (CANQF)?
